Clinical statistics of gynecologic cancers in Japan

Wataru Yamagami, Satoru Nagase, Fumiaki Takahashi, Kazuhiko Ino, Toru Hachisuga, Daisuke Aoki, Hidetaka Katabuchi

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Cervical, endometrial, and ovarian cancers, have both high morbidity and mortality among the gynecologic malignant tumors in Japan. The present study was conducted using both the population-based cancer registry and the gynecologic cancer registry to elucidate the characteristics of gynecologic malignant tumors in Japan. Based on nationwide estimates from the population-based cancer registry in Japan, the morbidities and mortality of cervical, endometrial, and ovarian cancers were obtained and used for analysis. Clinicopathologic factors for cervical cancer, endometrial cancer, ovarian cancer, including age, clinical stage, postsurgical stage, histological type, therapeutic strategy, and prognosis were retrieved from the gynecologic cancer registry published by the Japan Society of Obstetrics and Gynecology and used for analysis. The morbidities of cervical, endometrial, and ovarian cancers were 10,908, 13,606, and 9,384 women in 2012, respectively. The prevalence of endometrial cancer has significantly and consistently been increasing and represents the most common gynecologic malignant tumor in Japan. The mortalities of cervical, endometrial, and ovarian cancers were 2.1, 1.3, and 3.2 per 100,000 in 2012, respectively. In 2014, 52.2% of cervical cancer patients were classified as stage I, 22.5% as stage II, 10.2% as stage III, and 11.2% as stage IV. In addition, 71.9% of endometrial cancer patients were classified as stage I, 6.0% as stage II, 13.3% as stage III, and 7.5% as stage IV. Finally, 43.2% of ovarian cancer patients were classified as stage I, 9.1% as stage II, 27.6% as stage III, and 7.2% as stage IV. Twelve-point six percent of ovarian cancer patients received neoadjuvant chemotherapy.

Original languageEnglish
Pages (from-to)e32
JournalJournal of Gynecologic Oncology
Volume28
Issue number2
DOIs
Publication statusPublished - 2017 Mar 1
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Ovarian Neoplasms
Japan
Uterine Cervical Neoplasms
Registries
Neoplasms
Morbidity
Mortality
Gynecology
Population
Obstetrics
Drug Therapy

Keywords

  • Genital Neoplasms, Female
  • Japan
  • Mortality
  • Neoplasms
  • Prevalence
  • Registries
  • Stage

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Clinical statistics of gynecologic cancers in Japan. / Yamagami, Wataru; Nagase, Satoru; Takahashi, Fumiaki; Ino, Kazuhiko; Hachisuga, Toru; Aoki, Daisuke; Katabuchi, Hidetaka.

In: Journal of Gynecologic Oncology, Vol. 28, No. 2, 01.03.2017, p. e32.

Research output: Contribution to journalReview article

Yamagami, W, Nagase, S, Takahashi, F, Ino, K, Hachisuga, T, Aoki, D & Katabuchi, H 2017, 'Clinical statistics of gynecologic cancers in Japan', Journal of Gynecologic Oncology, vol. 28, no. 2, pp. e32. https://doi.org/10.3802/jgo.2017.28.e32
Yamagami, Wataru ; Nagase, Satoru ; Takahashi, Fumiaki ; Ino, Kazuhiko ; Hachisuga, Toru ; Aoki, Daisuke ; Katabuchi, Hidetaka. / Clinical statistics of gynecologic cancers in Japan. In: Journal of Gynecologic Oncology. 2017 ; Vol. 28, No. 2. pp. e32.
@article{608adcb245a1453ea33c534ce950aa0c,
title = "Clinical statistics of gynecologic cancers in Japan",
abstract = "Cervical, endometrial, and ovarian cancers, have both high morbidity and mortality among the gynecologic malignant tumors in Japan. The present study was conducted using both the population-based cancer registry and the gynecologic cancer registry to elucidate the characteristics of gynecologic malignant tumors in Japan. Based on nationwide estimates from the population-based cancer registry in Japan, the morbidities and mortality of cervical, endometrial, and ovarian cancers were obtained and used for analysis. Clinicopathologic factors for cervical cancer, endometrial cancer, ovarian cancer, including age, clinical stage, postsurgical stage, histological type, therapeutic strategy, and prognosis were retrieved from the gynecologic cancer registry published by the Japan Society of Obstetrics and Gynecology and used for analysis. The morbidities of cervical, endometrial, and ovarian cancers were 10,908, 13,606, and 9,384 women in 2012, respectively. The prevalence of endometrial cancer has significantly and consistently been increasing and represents the most common gynecologic malignant tumor in Japan. The mortalities of cervical, endometrial, and ovarian cancers were 2.1, 1.3, and 3.2 per 100,000 in 2012, respectively. In 2014, 52.2{\%} of cervical cancer patients were classified as stage I, 22.5{\%} as stage II, 10.2{\%} as stage III, and 11.2{\%} as stage IV. In addition, 71.9{\%} of endometrial cancer patients were classified as stage I, 6.0{\%} as stage II, 13.3{\%} as stage III, and 7.5{\%} as stage IV. Finally, 43.2{\%} of ovarian cancer patients were classified as stage I, 9.1{\%} as stage II, 27.6{\%} as stage III, and 7.2{\%} as stage IV. Twelve-point six percent of ovarian cancer patients received neoadjuvant chemotherapy.",
keywords = "Genital Neoplasms, Female, Japan, Mortality, Neoplasms, Prevalence, Registries, Stage",
author = "Wataru Yamagami and Satoru Nagase and Fumiaki Takahashi and Kazuhiko Ino and Toru Hachisuga and Daisuke Aoki and Hidetaka Katabuchi",
year = "2017",
month = "3",
day = "1",
doi = "10.3802/jgo.2017.28.e32",
language = "English",
volume = "28",
pages = "e32",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "2",

}

TY - JOUR

T1 - Clinical statistics of gynecologic cancers in Japan

AU - Yamagami, Wataru

AU - Nagase, Satoru

AU - Takahashi, Fumiaki

AU - Ino, Kazuhiko

AU - Hachisuga, Toru

AU - Aoki, Daisuke

AU - Katabuchi, Hidetaka

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Cervical, endometrial, and ovarian cancers, have both high morbidity and mortality among the gynecologic malignant tumors in Japan. The present study was conducted using both the population-based cancer registry and the gynecologic cancer registry to elucidate the characteristics of gynecologic malignant tumors in Japan. Based on nationwide estimates from the population-based cancer registry in Japan, the morbidities and mortality of cervical, endometrial, and ovarian cancers were obtained and used for analysis. Clinicopathologic factors for cervical cancer, endometrial cancer, ovarian cancer, including age, clinical stage, postsurgical stage, histological type, therapeutic strategy, and prognosis were retrieved from the gynecologic cancer registry published by the Japan Society of Obstetrics and Gynecology and used for analysis. The morbidities of cervical, endometrial, and ovarian cancers were 10,908, 13,606, and 9,384 women in 2012, respectively. The prevalence of endometrial cancer has significantly and consistently been increasing and represents the most common gynecologic malignant tumor in Japan. The mortalities of cervical, endometrial, and ovarian cancers were 2.1, 1.3, and 3.2 per 100,000 in 2012, respectively. In 2014, 52.2% of cervical cancer patients were classified as stage I, 22.5% as stage II, 10.2% as stage III, and 11.2% as stage IV. In addition, 71.9% of endometrial cancer patients were classified as stage I, 6.0% as stage II, 13.3% as stage III, and 7.5% as stage IV. Finally, 43.2% of ovarian cancer patients were classified as stage I, 9.1% as stage II, 27.6% as stage III, and 7.2% as stage IV. Twelve-point six percent of ovarian cancer patients received neoadjuvant chemotherapy.

AB - Cervical, endometrial, and ovarian cancers, have both high morbidity and mortality among the gynecologic malignant tumors in Japan. The present study was conducted using both the population-based cancer registry and the gynecologic cancer registry to elucidate the characteristics of gynecologic malignant tumors in Japan. Based on nationwide estimates from the population-based cancer registry in Japan, the morbidities and mortality of cervical, endometrial, and ovarian cancers were obtained and used for analysis. Clinicopathologic factors for cervical cancer, endometrial cancer, ovarian cancer, including age, clinical stage, postsurgical stage, histological type, therapeutic strategy, and prognosis were retrieved from the gynecologic cancer registry published by the Japan Society of Obstetrics and Gynecology and used for analysis. The morbidities of cervical, endometrial, and ovarian cancers were 10,908, 13,606, and 9,384 women in 2012, respectively. The prevalence of endometrial cancer has significantly and consistently been increasing and represents the most common gynecologic malignant tumor in Japan. The mortalities of cervical, endometrial, and ovarian cancers were 2.1, 1.3, and 3.2 per 100,000 in 2012, respectively. In 2014, 52.2% of cervical cancer patients were classified as stage I, 22.5% as stage II, 10.2% as stage III, and 11.2% as stage IV. In addition, 71.9% of endometrial cancer patients were classified as stage I, 6.0% as stage II, 13.3% as stage III, and 7.5% as stage IV. Finally, 43.2% of ovarian cancer patients were classified as stage I, 9.1% as stage II, 27.6% as stage III, and 7.2% as stage IV. Twelve-point six percent of ovarian cancer patients received neoadjuvant chemotherapy.

KW - Genital Neoplasms, Female

KW - Japan

KW - Mortality

KW - Neoplasms

KW - Prevalence

KW - Registries

KW - Stage

UR - http://www.scopus.com/inward/record.url?scp=85027459784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027459784&partnerID=8YFLogxK

U2 - 10.3802/jgo.2017.28.e32

DO - 10.3802/jgo.2017.28.e32

M3 - Review article

VL - 28

SP - e32

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 2

ER -